The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of ...
The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results